Compare Cassava Sciences Inc (FLNA) vs HubSpot Inc (HUBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs HubSpot Inc — how do they compare? Cassava Sciences Inc trades at $1.08 (market cap $53.14M), while HubSpot Inc trades at $218.74 (market cap $11.02B). The key difference: HubSpot Inc is far larger — about 207.4× Cassava Sciences Inc's market cap, and HubSpot Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | HUBS | |
|---|---|---|
Market Cap | $53.14M | $11.02B |
Sector | Health | Technology |
52-Week High | $4.64 | $560.90 |
52-Week Low | $1.09 | $170.39 |
Enterprise Value | -$33.43M | $9.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
HubSpot (HUBS) trades at $209.68, down 3.64% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $268.75. The company reported Q1 2026 EPS of $2.72, beating estimates, and shows strong revenue growth, reaching $3.13B in 2025. Positive sentiment is driven by AI integration and customer expansion, with 80.85% of analysts rating it a Buy.
The outlook for HUBS is positive, supported by robust revenue growth, expanding AI capabilities, and consistent earnings beats. Key risks include high valuation multiples and competitive pressures in the CRM space. Investors should monitor execution on AI monetization and margin improvement for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →
